2025-05-13 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the data provided, formatted as requested.

## Eli Lilly and Co (LLY) Stock Analysis

**Ticker:** LLY
**Company Name:** Eli Lilly and Co.
**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that develops and markets a wide range of medicines.

### 1. Performance vs. S&P 500 (VOO)

*   **LLY Cumulative Return:** 274.21%
*   **VOO Cumulative Return:** 93.97%
*   **Absolute Spread:** 180.24%
*   **Spread Range:** (Min: -27.8, Max: 339.1)
*   **Relative Spread:** 56.7

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period. The absolute spread of 180.24% highlights this outperformance. The relative spread of 56.7 indicates that the current spread is positioned towards the middle of its historical range relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
|------------|--------|--------|---------|-------|--------|
| 2015-2017  | 14.0%  | 55.9%  | -19.0%  | 0.1   | 67.7   |
| 2016-2018  | 42.0%  | 58.6%  | 21.0%   | 0.1   | 95.0   |
| 2017-2019  | 55.0%  | 58.6%  | 21.0%   | 1.4   | 110.4  |
| 2018-2020  | 57.0%  | 58.6%  | 27.0%   | 0.7   | 144.7  |
| 2019-2021  | 116.0% | 60.5%  | 55.0%   | 0.4   | 240.3  |
| 2020-2022  | 111.0% | 64.9%  | 102.0%  | 0.3   | 322.6  |
| 2021-2023  | 152.0% | 64.9%  | 132.0%  | 0.3   | 519.0  |
| 2022-2024  | 171.0% | 72.1%  | 150.0%  | 0.3   | 691.9  |
| 2023-2025  | 106.0% | 76.8%  | 74.0%   | 0.2   | 678.3  |

**Analysis:**

*   **CAGR:** Compounded Annual Growth Rate has been impressive, especially in recent years (2019-2024).
*   **MDD:** Maximum Drawdown shows the potential downside risk, with MDD increasing over time, indicating higher volatility.
*   **Alpha:** Consistently positive and increasing alpha indicates LLY's ability to generate excess returns compared to its benchmark.
*   **Beta:** Beta values are generally low, suggesting that LLY's price is less sensitive to overall market movements.
*   **Cap(B):** Market capitalization has grown significantly, reflecting the company's strong performance.

### 2. Recent Price Action

*   **Current Price:** 755.57
*   **Previous Close:** 734.57
*   **Change:** 2.86%
*   **5-day Moving Average:** 758.686
*   **20-day Moving Average:** 809.9845
*   **60-day Moving Average:** 827.8155

**Analysis:**

The stock price shows a strong positive change from the previous close, indicating a recent upward movement. However, the current price is below all three moving averages (5-day, 20-day, and 60-day), suggesting a potential short-term downward trend or consolidation after a pullback.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3676 (Low Risk)
*   **RSI:** 39.21 (Approaching Oversold)
*   **PPO:** -1.3063 (Below Zero, Suggesting Potential Downtrend)
*   **Recent (20-day) Relative Spread Change:** -8.9 (Negative, indicating short-term underperformance relative to VOO)
*   **Expected Return:** 127.7% (Long-term excess return potential vs. S&P 500)

**Analysis:**

*   The MRI indicates a low-risk environment.
*   The RSI value suggests that the stock is approaching oversold conditions, which could signal a potential buying opportunity.
*   The negative PPO suggests a possible downtrend in price momentum.
*   The recent negative change in relative spread (-8.9) indicates that LLY has underperformed the S&P 500 in the short term.
*   The high expected return suggests a strong long-term outlook for LLY compared to the S&P 500, assuming a buy-and-hold strategy.
* The positive change of 2.86% may signal a recent issue causing price volitility.

### 4. Recent News & Significant Events

*   **2025-05-13:** Major business developments, regulatory changes, or market events impacting Eli Lilly.
*   **2025-05-12:** Analyst discussions regarding LLY's recent performance, industry trends, and global economic factors.
*   **2025-05-10:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-05-11:** Market experts highlighting risks and opportunities for LLY, advising monitoring of news and announcements.

**Analysis:**

Recent news indicates that Eli Lilly is experiencing notable activity, including potential market-moving events and analyst scrutiny. This suggests that investors should closely monitor news and company announcements for short-term developments.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2024-04-30 | 2.49 | 8.77 B$    |
| 2025-05-01 | 2.49 | 8.77 B$    |

**Analysis:**

The provided earnings data shows fluctuating EPS and revenue. Most recent quarter (2025-05-01) show solid EPS and Revenue. The trend in revenue has been generally positive, indicating growth in the company's sales.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |
| 2024-06-30   | $11.30B   | 80.80%        |
| 2024-03-31   | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-03-31   | $15.76B   | 17.50%    |
| 2024-12-31   | $14.19B   | 31.07%    |
| 2024-09-30   | $14.24B   | 6.81%     |
| 2024-06-30   | $13.56B   | 21.88%    |
| 2024-03-31   | $12.81B   | 17.51%    |

**Analysis:**

*   **Revenue:** Revenue has generally increased over the past five quarters, indicating solid growth.
*   **Profit Margin:** The company maintains a very high and stable profit margin, indicating efficient operations and strong pricing power.
*   **Equity:** Total equity has also been on an upward trend, reflecting the company's growing asset base.
*   **ROE:** Return on Equity has fluctuated, but overall remains strong, especially in Q4 2024.

### 7. 종합적인 분석 (Overall Analysis)

Eli Lilly and Co. (LLY) exhibits strong fundamentals and significant outperformance relative to the S&P 500 (VOO).  The company demonstrates impressive revenue growth, high profit margins, and a robust expected return. Recent news suggests dynamic developments, and the stock price exhibits a sharp recent increase.

**Key Takeaways:**

*   **Strong Performance:** LLY has significantly outperformed the S&P 500 and has consistently generated positive alpha.
*   **Solid Financials:** The company shows robust revenue growth, high profit margins, and improving equity.
*   **Technical Considerations:**  The stock is showing signs of potential short-term weakness based on moving averages, but is near oversold territory based on RSI, which could present a buying opportunity for long-term investors.
*   **Market Context:**  Recent news indicates significant activity around the stock, warranting close monitoring of company announcements and market developments.
*   **Long-Term Potential:**  The high expected return suggests that LLY may be a favorable investment for long-term, buy-and-hold investors.
